Veritable’s United Therapeutics UTHR Stock Holding History

Veritable’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-928	Closed	-$205K	–	760
2023 Q2	$205K	Sell	928 -10	-1%	-$2.21K	﹤0.01%	840
2023 Q1	$210K	Buy	938 +16	+2%	+$3.94K	﹤0.01%	826
2022 Q4	$256K	Buy	+922	New	+$233K	﹤0.01%	709
2022 Q3	–	Sell	-858	Closed	-$202K	–	900
2022 Q2	$202K	Buy	+858	New	+$174K	﹤0.01%	824

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Veritable's UTHR Position: Q3 2023 in Review

Veritable sold out of United Therapeutics (UTHR) in Q3 2023, closing a stake of 928 shares — an estimated $205K sold.

Veritable first reported a position in UTHR in Q2 2022 and held it in 4 quarters. The position peaked at $256K in Q4 2022. 508 funds tracked by Wall St. Rank hold UTHR as of Q3 2023.

Veritable reported no remaining United Therapeutics position as of Q3 2023 after selling out during the quarter.
Veritable sold 928 United Therapeutics shares in Q3 2023, an estimated $205K.
Veritable first reported a position in United Therapeutics in Q2 2022 and held it in 4 quarters.
Veritable's United Therapeutics position peaked at $256K in Q4 2022.
508 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2023.

Based on Veritable's 13F filing for Q3 2023.